FORMULATION, DEVELOPMENT AND CHARACTERIZATION OF EFFECTIVE NIOSOMAL DRUG DELIVERY SYSTEM FOR THE TREATMENT OF DIABETES MELLITUS

In the present study, gliclazide-loaded niosomes are formulated and evaluated for their in vitro as well as in vivo characteristic in an attempt to improve the oral bioavailability of the drug. Formulation of niosomes was optimized for highest percentage of drug entrapment. Microscopic observation confirmed that all particles were uniform in size and shape. The entrapment efficiency was determined by separating the unentrapped drug using dialysis. The in vitro release studies of drug from niosomes exhibited a prolonged drug release as observed over a period of 24 h. The positive values of zeta potential indicated that the gliclazide niosomes were stabilized by electrostatic repulsive forces. Results from stability study have shown that the drug leakage from the vesicles was least at 4ºC followed by 25 and 37ºC. The niosomes showing maximum entrapment and suitable release rate were selected for in vivo evaluation. In conclusion, the niosomal formulation could be a promising delivery system for gliclazide with improved bioavailability and prolonged drug release profile. KEYWORDS: Heme Oxygenase Inhibitor, HO-1, 2D QSAR, 3D QSAR, kNN-MFA